Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Yannis K. Valtis, Yael Flamand, Shai Shimony, Andrew E. Place, Lewis B. Silverman, Lynda M. Vrooman, Andrew M. Brunner, Stephen E. Sallan, Martha Wadleigh, Jacqueline S. Garcia, Eric S. Winer, Ilene Galinsky, Julie Bergeron, Julie Asch, Matthew D. Seftel, Richard M Stone, Marlise R. Luskin, Daniel J. DeAngelo

Blood (2023) 142 (Supplement 1): 4238.

https://doi.org/10.1182/blood-2023-181014

Published: 2023

Journal Articles

Has MRD graduated from its adolescence in ALL?

Matthew D. Seftel

Blood (2021) 137 (14): 1846–1847.

https://doi.org/10.1182/blood.2020009409

Published: 2021

Journal Articles

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Sarit Assouline, MD, Shen Li, MD, Christian Gisselbrecht, MD, Patrick Fogarty, Annette E. Hay, Eric Van Den Neste, MD, Lois E. Shepherd, Norbert Schmitz, MD, Tara Baetz, Armand Keating, MD, Sue Robinson, MD, Matthew D. Seftel, FRCP,FRCPC,MPH,MD, Caterina Stelitano, Marina S. Djurfeldt, Ralph Meyer, Bingshu E. Chen, Michael Crump, MD FRCPC

Blood (2019) 134 (Supplement_1): 768.

https://doi.org/10.1182/blood-2019-124879

Published: 2019

Journal Articles

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Blood (2016) 128 (22): 679.

https://doi.org/10.1182/blood.V128.22.679.679

Published: 2016

Journal Articles

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Kristjan Paulson, MD, Ruta Brazauskas, PhD, Naya He, MPH, David Szwajcer, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Yoshiko Atsuta, MD PhD, Jignesh D Dalal, MD, Theresa Hahn, PhD, Carmem Bonfim, MD, Nandita Khera, MD, Linda J. Burns, MD, Lih-Wen Mau, PhD MPH, Navneet S. Majhail, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 842.

https://doi.org/10.1182/blood.V128.22.842.842

Published: 2016

Journal Articles

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

Craig Speziali, MD MSc, FRCPC, Andrew Daly, MD FRCPC, Mohamed Abuhaleeqa, MD, Janet Nitta, Yasser Abou Mourad, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kristjan Paulson, MD FRCPC

Blood (2016) 128 (22): 663.

https://doi.org/10.1182/blood.V128.22.663.663

Published: 2016

Journal Articles

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Ming Han, Alli Murugesan, Nizar J. Bahlis, Kevin Song, Darrell White, Christine Chen, Matthew D. Seftel, Kang Howsen-Jan, Donna Reece, Keith Stewart, Yagang Xie, Annette E. Hay, Lois Shepherd, Marina Djurfeldt, Liting Zhu, Ralph M. Meyer, Bingshu E. Chen, Tony Reiman

Blood (2016) 128 (5): 732–735.

https://doi.org/10.1182/blood-2016-06-716902

Published: 2016

Includes: Supplemental data

Journal Articles

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., P.Stat., Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Aaron D. Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Mohamed Shanavas, MD FRACP, FRCPA, Andrzej Lutynski, MD, Amr Rostom, MD, Anna Rydlewski, MD, Dina Khalaf, BSc, MSc, MD, Karen W.L. Yee, MD

Blood (2015) 126 (23): 4893.

https://doi.org/10.1182/blood.V126.23.4893.4893

Published: 2015

Journal Articles

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Daniel J. DeAngelo, MD PhD, Kristen Stevenson, MS, Donna S Neuberg, ScD, Lewis B. Silverman, MD, Karen K. Ballen, MD, Julie D. Asch, MD, Yasser Abou Mourad, MD, Kristjan Paulson, MD FRCPC, Matthew D. Seftel, MBChB, FRCP(C), MRCP, David Avigan, MD, Julie Bergeron, MD, Stephen Couban, MD, William Blum, MD, John Storring, MD, Martha Wadleigh, MD, David P. Steensma, MD, Jeffrey Supko, PhD, Stephen E. Sallan, MD, Richard M. Stone, MD

Blood (2015) 126 (23): 80.

https://doi.org/10.1182/blood.V126.23.80.80

Published: 2015

Journal Articles

Time to Diagnosis and Treatment of Lymphoma: A Canadian Population Based Study

Pamela Skrabek, FRCPC, Oliver Bucher, MSc, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Donna Turner, PhD

Blood (2015) 126 (23): 2098.

https://doi.org/10.1182/blood.V126.23.2098.2098

Published: 2015

Journal Articles

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Ming Han, BSc., Alli Murugesan, MSc, PhD, Nizar J Bahlis, MD, Kevin Song, Darrell White, MD MSc, FRCPC, FACP, Christine Chen, MD, Matthew D. Seftel, MBChB, FRCP(C), MRCP, Kang Howsen-Jan, MD, Donna Reece, Keith Stewart, MD, Yagang Xie, MD PhD FCCMG, Annette E Hay, MB ChB, Lois Shepherd, MD, Bingshu E Chen, PhD, Marina Djurfeldt, MSc., Tony Reiman, MD

Blood (2015) 126 (23): 2960.

https://doi.org/10.1182/blood.V126.23.2960.2960

Published: 2015

Journal Articles

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Matthew D. Seftel, MDMPH FRCPC, Donna Neuberg, ScD, Mei-Jie Zhang, PhD, Hai-Lin Wang, MPH, Julie Bergeron, MD FRCPC, Stephen Couban, MD FRCPC, Daniel J. DeAngelo, MD PhD, Marcos J de Lima, MD, Steven M. Devine, MD, Mary Eapen, MBBS, Mary M. Horowitz, MD MS, Marcelo C. Pasquini, MD MS, J. Douglas Rizzo, MD, Wael Saber, MD MS, Stephen E. Sallan, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD

Blood (2014) 124 (21): 319.

https://doi.org/10.1182/blood.V124.21.319.319

Published: 2014

Journal Articles

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Justyna Bartoszko, Tony Panzerella, Anthea Lau, Naheed Alam, MBBS,MD, Aaron D Schimmer, MDPhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Andre C Schuh, MD FRCPC, Mohamed Shanavas, MD FRACP, FRCPA, Karen W.L. Yee, MDFRCPC, Vikas Gupta, MD FRCP, FRCPath

Blood (2014) 124 (21): 3180.

https://doi.org/10.1182/blood.V124.21.3180.3180

Published: 2014

Journal Articles

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

Marc Poch Martell, MD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, Vikas Gupta, MD FRCP, FRCPath, Jeffrey H. Lipton, MD PhD, John Kuruvilla, MD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD, Dennis Kim, MDPhD

Blood (2014) 124 (21): 3936.

https://doi.org/10.1182/blood.V124.21.3936.3936

Published: 2014

Journal Articles

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

Fotios V. Michelis, MDPhD, Hans A. Messner, MD PhD, Jieun Uhm, MD, Naheed Alam, MBBS,MD, David Loach, MD, Laura McGillis, NP, Anna Lambie, NP, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Dennis D. Kim, MD PhD

Blood (2014) 124 (21): 2529.

https://doi.org/10.1182/blood.V124.21.2529.2529

Published: 2014

Journal Articles

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Sita D. Bhella, MD, Eshetu G Atenafu, M.Sc., Andre C Schuh, MD FRCPC, Mark D Minden, MDPhD, Aaron D Schimmer, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS, MD, Andrzej Lutynski, MD, Amr Rostom, MD CFPC, Anna Rydlewski, MD, Karen Yee, MD

Blood (2014) 124 (21): 5285.

https://doi.org/10.1182/blood.V124.21.5285.5285

Published: 2014

Journal Articles

Serum Albumin Level < 32 g/l on Day 30 Can Predicts Higher Risk of Non-Relapse Mortality in Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation

Feras Alfraih, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD, Jeffrey H. Lipton, MD PhD, Hans A. Messner, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Jieun Uhm, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2014) 124 (21): 5930.

https://doi.org/10.1182/blood.V124.21.5930.5930

Published: 2014

Journal Articles

Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm By Using 10-Colour Flow Cytometry and Achievement of Remission By Hypercvad Therapy

Uday Deotare, MD DM, Elizabeth Hyjek, MD PhD, Anna Porwit, MDPhD, Rumina Musani, MDFCAP, FRCPC, David Barth, MD FRCPC, Emina Torlakovic, MD, Anne Tierens, MD PhD, Aaron D Schimmer, MDPhD, Andre C Schuh, MD FRCPC, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Matthew D. Seftel, MRCP, FRCPC, MPH, Naheed Alam, MBBS,MD, Karen W.L. Yee, MDFRCPC

Blood (2014) 124 (21): 2365.

https://doi.org/10.1182/blood.V124.21.2365.2365

Published: 2014

Journal Articles

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Fotios V. Michelis, MDPhD, Rouslan Kotchetkov, MD, Aamir Azeem, Rebecca M. Grunwald, Jieun Uhm, MD, Naheed Alam, MBBS, MD, Anna Lambie, NP, Laura McGillis, NP, David Loach, MD, Vikas Gupta, MD FRCP, FRCPath, John Kuruvilla, MD FRCPC, Jeffrey H. Lipton, MD PhD, Dennis D. Kim, MD PhD, Matthew D. Seftel, MRCP, FRCPC, MPH, Hans A. Messner, MD PhD

Blood (2014) 124 (21): 1237.

https://doi.org/10.1182/blood.V124.21.1237.1237

Published: 2014

Journal Articles

Quality of Care in Blood and Marrow Transplantation – a Systematic Review in Order to Define a Quality Framework and Develop Quality Indicators

Vishal Kukreti, MD, Emma Mauti, BSc., Roxanne Macaskill, BSc, RN, BScN, MN, MHSc, Christine Chen, MDFRCPC, Matthew D. Seftel, MRCP, FRCPC, MPH

Blood (2014) 124 (21): 1311.

https://doi.org/10.1182/blood.V124.21.1311.1311

Published: 2014

NARROW

Updated Results on a Multicenter Phase II Study of a Dose Intensified Pediatric Regimen in Adults with Acute Lymphoblastic Leukemia: The 06-254 DFCI ALL Consortium Trial

Has MRD graduated from its adolescence in ALL?

Event-Free Survival As a Surrogate for Overall Survival in Relapsed DLBCL after Autologous Transplant: A Subgroup Analysis of LY.12 and Coral

Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia

Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis

Fludarabine and Busulfan Plus Low Dose TBI Versus Cyclophosphamide Plus TBI in Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Equivalent Outcomes in a Recent, Large Canadian Multicenter Cohort

A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma

Front-Line FLAG-IDA and Nove-HiDAC Chemotherapy Improves Overall Survival (OS) and Complete Remission Rates (CR) for Patients with Secondary or Therapy-Related AML Compared to 3&7

A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial

Time to Diagnosis and Treatment of Lymphoma: A Canadian Population Based Study

A Pharmacogenetic Study of the NCIC CTG Clinical Trial My.10: Single Nucleotide Polymorphisms, Prognosis, and Predicting Benefit from IMiD® Compound Maintenance Therapy Following Autologous Stem Cell Transplant for Multiple Myeloma

Superiority of Pediatric Chemotherapy over Allogeneic Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult ALL in First Complete Remission: A Combined Analysis of Dana-Farber ALL Consortium and CIBMTR Cohorts

Comparison of the Impact of Two Different Definitions of Red-Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF)

Validation of Favourable Impact of Large Granular Lymphocytosis after Allogeneic Hematopoietic Cell Transplantation

Evaluation of the Disease Risk Index on Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

FLAG-IDA Has Significant Activity As Frontline Induction or Salvage Therapy for Patients with High Risk and/or Relapsed or Refractory Acute Myeloid Leukemia (AML)

Serum Albumin Level < 32 g/l on Day 30 Can Predicts Higher Risk of Non-Relapse Mortality in Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation

Diagnosis of Blastic Plasmacytoid Dendritic Cell Neoplasm By Using 10-Colour Flow Cytometry and Achievement of Remission By Hypercvad Therapy

Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

Quality of Care in Blood and Marrow Transplantation – a Systematic Review in Order to Define a Quality Framework and Develop Quality Indicators

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only